Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals
DelveInsight's 'Respiratory Syncytial Virus Pipeline Insight, 2024' report details 50+ companies developing 50+ therapies, including Nirsevimab, Sisunatovir, and RSVpreF, across various stages of clinical trials. Key companies include GSK, Pfizer, and Sanofi, with recent successes like GSK's Arexvy vaccine and MSD's clesrovimab. The report covers mechanism of action, route of administration, and market dynamics.
Insilico Medicine appoints Carol Satler, MD.
Insilico Medicine appoints Carol Satler, M.D., PhD, as VP for Non-oncology Clinical Development, to lead validation of ISM001-055 for idiopathic pulmonary fibrosis and strategic planning for non-oncology assets. Satler, with 20+ years of experience at Pfizer, Sanofi, Bayer, Takeda/Millennium, Puretech Health, and Gilead, aims to accelerate clinical validation and bring transformative therapies to market using AI.
Social media engagement boosts rare disease outreach
Chris Adams, CEO of Andarix Pharmaceuticals, discusses using social media and PRISM software for rare disease trial patient recruitment at the Outsourcing in Clinical Trials conference in Boston. Adams highlights a 40% response rate, emphasizing patient motivation, but warns about misinformation. He also recommends leveraging patient registries like IAMRARE, CoRDS, and RDCRN for targeted recruitment.
Turning tides for endotoxin testing
US regulators will accept alternatives to horseshoe crab blood for drug quality assurance testing in November, easing industry reliance on the animal.
Opinion: New Therapies Are Set to Upend Treatment of Genetic Disorder AATD
Alpha-1 antitrypsin deficiency (AATD) affects 1 in 3,500, causing liver/lung damage. Current treatment, augmentation therapy, doesn't reverse damage. Multiple companies develop candidates to prevent/reverse damage, with RNAi, RNA-editing, and base editing therapies showing promise. Vertex's AATD candidates failed, while Arrowhead, Sanofi, Beam Therapeutics, Wave Life Sciences, and Korro Bio advance their treatments. Augmentation therapy may become obsolete within 5-10 years.
Dupilumab Proves Effective in Chronic Spontaneous Urticaria
Dupilumab significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) uncontrolled by H1-antihistamines, according to the phase III LIBERTY-CUPID study C. Dupilumab showed an 8.64-point reduction in itch severity and a 15.86-point reduction in urticaria activity severity compared to placebo. The study supports regulatory resubmission in the U.S. for dupilumab as a targeted therapy for CSU.
Can Merrimack Get A High Five?
Merrimack Pharmaceuticals, a biotech company focused on cancer treatment, has five oncology candidates in clinical development. Its most advanced candidate, MM-398, is in a global phase III study for pancreatic cancer. Merrimack also has candidates like MM-121, developed with Sanofi, in various cancer trials. Despite significant operating losses, the company's IPO raised $100.5 million, funding operations into the second half of 2013.
Orphan Indication Drugs Market Forecast 2031
The Orphan Indication Drugs market, focusing on rare diseases, is driven by government support and investment, offering lucrative opportunities for pharmaceutical companies. Key players include Bristol-Myers Squibb, Roche, Novartis, and Johnson & Johnson. The market is segmented by type (biologics, non-biologics) and application (hospital pharmacy, retail pharmacy, online sales), with growth potential in both established and emerging markets.
Lebrikizumab Demonstrates Efficacy in Itch and Skin Clearance Among Patients With AD
Lilly presented phase 3b ADapt study results at the 2024 Fall Clinical Dermatology Conference, showing lebrikizumab's efficacy in improving skin symptoms and quality of life in patients with moderate to severe atopic dermatitis previously treated with dupilumab. The study involved 86 patients, with 83% achieving at least a 4-point improvement in Dermatology Life Quality Index scores by weeks 16 and 24. Safety data indicated mild to moderate adverse events, primarily injection site reactions and mild infections.
© Copyright 2025. All Rights Reserved by MedPath